Immunization of mice with lipopeptides bypasses the prerequisite for adjuvant. Immune response of BALB/c mice to human immunodeficiency virus envelope glycoprotein
- PMID: 1385524
Immunization of mice with lipopeptides bypasses the prerequisite for adjuvant. Immune response of BALB/c mice to human immunodeficiency virus envelope glycoprotein
Abstract
In vivo priming of CTL requires the association with MHC class I molecules of peptides derived from the processing of endogenously produced proteins. Immunization with exogenous proteins or peptides rarely induces MHC class I-restricted CTL unless they are associated with lipidic compounds. The capacity to induce CTL was compared in synthetic peptides and simple lipopeptides containing the Immunodominant MHC class I H-2Dd-restricted T-cell epitope of HIV-1 gp160. In contrast with free peptides in saline, lipopeptides induced strong primary CTL responses in vivo. These CTL were able to lyse cells infected with a recombinant vaccinia virus expressing the HIV-1 env gene. Priming of CTL was also successful when using 16-amino acid lipopeptides as 34-amino acid lipopeptides, suggesting that several epitopes might be included in a single construct. In vivo priming of CTL also requires CD4+ T cell help. We therefore searched for Th cell activation after priming with lipopeptides. Our results show that, as with CTL induction, Th cell activation with lipopeptides did not require mixing with adjuvant. In addition, lipopeptides were also efficient at stimulating antibody-mediated responses. Our results show that a single lipopeptidic construct can induce a total immune response, which is of importance in vaccine development.
Similar articles
-
Helper-cytotoxic T lymphocyte (CTL) determinant linkage required for priming of anti-HIV CD8+ CTL in vivo with peptide vaccine constructs.J Immunol. 1994 Jan 15;152(2):549-56. J Immunol. 1994. PMID: 8283036
-
Cytotoxic T cell repertoire selection. A single amino acid determines alternative class I restriction.J Immunol. 1994 Jun 15;152(12):5603-12. J Immunol. 1994. PMID: 7515908
-
Broad recognition of cytotoxic T cell epitopes from the HIV-1 envelope protein with multiple class I histocompatibility molecules.J Immunol. 1992 Mar 15;148(6):1657-67. J Immunol. 1992. PMID: 1371784
-
Progress toward an artificial vaccine for HIV: identification of helper and cytotoxic T-cell epitopes and methods of immunization.Biotechnol Ther. 1991;2(1-2):123-35. Biotechnol Ther. 1991. PMID: 1726961 Review.
-
Synthetic lipopeptides as novel adjuvants.Res Immunol. 1992 Jun;143(5):548-53; discussion 579-80. doi: 10.1016/0923-2494(92)80067-u. Res Immunol. 1992. PMID: 1439136 Review.
Cited by
-
Vaccine-induced virus-neutralizing antibodies and cytotoxic T cells do not protect macaques from experimental infection with simian immunodeficiency virus SIVmac32H (J5).J Virol. 1995 Oct;69(10):6289-96. doi: 10.1128/JVI.69.10.6289-6296.1995. J Virol. 1995. PMID: 7666529 Free PMC article.
-
Lipids and retroviruses.Lipids. 2000 Feb;35(2):123-30. doi: 10.1007/BF02664760. Lipids. 2000. PMID: 10757541 Review.
-
Phase I/II randomized trial of safety and immunogenicity of LIPO-5 alone, ALVAC-HIV (vCP1452) alone, and ALVAC-HIV (vCP1452) prime/LIPO-5 boost in healthy, HIV-1-uninfected adult participants.Clin Vaccine Immunol. 2014 Nov;21(11):1589-99. doi: 10.1128/CVI.00450-14. Epub 2014 Sep 24. Clin Vaccine Immunol. 2014. PMID: 25253665 Free PMC article. Clinical Trial.
-
Antibody and cytotoxic T-cell responses to soluble hepatitis B virus (HBV) S antigen in mice: implication for the pathogenesis of HBV-induced hepatitis.J Virol. 1994 Mar;68(3):1418-25. doi: 10.1128/JVI.68.3.1418-1425.1994. J Virol. 1994. PMID: 8107205 Free PMC article.
-
Adenovirus hexon protein is a potent adjuvant for activation of a cellular immune response.J Virol. 2002 Jan;76(1):127-35. doi: 10.1128/jvi.76.1.127-135.2002. J Virol. 2002. PMID: 11739678 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Molecular Biology Databases
Research Materials